37 Matching Annotations
  1. Last 7 days
    1. 68-year-old male patient with HCM

      Case#: V-1; male; age 68

      DiseaseAssertion: Familial hypertrophic cardiomyopathy

      FamilyInfo: HCM was reported in the proband’s father and three daughters. The same heterozygous TNNT2 Δ160E variant was identified in all three daughters

      ParentalTesting: NR

      CasePresentingHPOs: HP:0001712 HP:0012664 HP:4000141 HP:0004756

      CaseHPOFreeText: Left ventricular hypertrophy; progressive left ventricular systolic dysfunction; left ventricular enlargement; cardiomyocyte hypertrophy; sustained ventricular tachycardia; advanced heart failure

      CaseNotHPOs: NR

      CaseNotHPOFreeText: NR

      CasePreviousTesting: Diagnosed with HCM at age 25; no previous genetic testing reported

      Genotyping Method: Ion AmpliSeq cardiovascular research panel screening 404 genes, with direct Sanger sequencing confirmation

      FunctionalAnalysis: Patient-derived and isogenic CRISPR/Cas9-edited iPSC-derived cardiomyocytes showed prolonged calcium decay, impaired relaxation, cardiomyocyte hypertrophy, and altered calcium-regulated signaling. EGCG partially improved the calcium and relaxation abnormalities.

      Variant: TNNT2 c.478_480del, p.Δ160E; in-frame 3-bp deletion

      ClinVar: 43648

      CAID: CA004651

      gnomAD: NR

    1. 33‐year‐old male

      Case#: 33-year-old male

      DiseaseAssertion: obstructive HCM

      FamilyInfo: Along with his mother 2 uncles, and a male cousin also suffer from HCM (Pedigree)

      ParentalTesting: Mother has HCM

      CasePresentingHPOs: HP:0031352

      CaseHPOFreeText: (exertional) chest tightness , and palpitations for over a year

      CaseNotHPOs: not reported

      CaseNotHPOFreeText: not reported

      CasePreviousTesting: 12‐lead electrocardiography, transthoracic echocardiography, and other comprehensive cardiac assessments

      Genotyping Method: Myocardial tissue was obtained after he underwent a myectomy from proband

      Peripheral venous blood and saliva samples were collected from proband and seven family members, whole exome sequencing, Sanger sequencing

      FunctionalAnalysis: MYH6 c.804G>C, wild‐type and mutant minigene constructs were generated and transfected into HeLa and 293 T cells

      Variant: MYBPC3 (c.787 G>A)

      ClinVar: 161315

      CAID: CA015857

      gnomAD: 11-47369442-C-T

      AdditionalInfo: PCR was conducted to amplify fragments of MYH6 variant

    1. Table 1. Clinical findings of individuals with Distal Arthrogryposis due to heterozygous variants in ACTC1.

      Case#:Male, age 16-20

      DiseaseAssertion:multiple pterygium syndrome and cardiomyopathy

      CasePresentingHPOs: HP:0006380, HP:0001838, HP:0001762, HP:0002987, HP:0009760, HP:0006394, HP:0000494, HP:0000508, HP:0000308, HP:0005986, HP:0002650, HP:0003273, HP:0001638, HP:0001631, HP:0001629,HP:003419, HP:000178, HP:002567, HP:0001561

      Short stature, Knee contractures, Vertical talus, Equinovarus/clubfoot, Elbow contractures, Webbed elbow, Limited forearm supination, Hypoplastic flexion creases, Downslanting palpebral fissures, Ptosis, Microretrognathia, Low-set ears, Limited neck rotation, Webbed neck, Scoliosis, Hip contractures, Cardiomyopathy, Atrial septal defect,Ventricular septal defect

      CaseNotHPOFreeText: Hypoplastic flexion creases,

      Genotyping Method: Exome Sequencing

      FunctionalAnalysis: "a de novo variant, c.553C>T, p.Arg185Trp", heterozygous

      Variant: NM_005159.5(ACTC1) ClinVar:45183 CAID:CA013.9824

      AdditionalInfo: Genomic Coordinates chr15:g.35084672G>A,

    1. Patients 2 and 3, monozygotic twins

      Case2: Sex not stated, age 8 months at diagnosis, ethnicity not stated

      DiseaseAssertion: Restrictive cardiomyopathy (RCM)

      FamilyInfo: Patients 2 and 3, monozygotic twins, were diagnosed with RCM at the age of 8 and 13 months, respectively. No familial history of cardiac disorders was reported in the R170W case, parental testing confirmed that the R170W variant occurred de novo (however, no parental proof was performed)

      ParentalTesting: Parental testing confirmed that the R170W variant occurred de novo (however, no parental proof was performed). Parents do not carry the variant

      CasePresentingHPOs: HP:0001723, HP:0002875, HP:0005110

      CaseHPOFreeText: Echocardiographic examination revealed a restrictive filling pattern and enlarged atria. Both children died at the age of 12 and 18 months, respectively, due to congestive heart failure and atrial fibrillation

      CaseNotHPOs: NR

      CaseNotHPOFreeText: NR

      CasePreviousTesting: NR

      Genotyping Method: Total genomic DNA was extracted from peripheral blood using FlexiGene DNA Kit (Qiagen) according to the manufacturer’s protocol. The TNNI3 gene was screened for mutations using dye terminator sequencing. In both cases additional target sequencing including a panel of 108 cardiomyopathy- and channelopathy-associated genes was performed using Illumina MiSeq as previously described

      FunctionalAnalysis: Functional analysis performed on recombinant proteins. Both cTnI-R170G/W strongly enhanced the Ca2+-sensitivity of skinned fibres, as is typical for RCM-mutations. Both mutants strongly enhanced the affinity of troponin (cTn) to tropomyosin compared to wildtype cTn. The stability of reconstituted thin filaments was reduced as revealed by electron microscopy.

      Variant: NM_000363.5:c.508C>T (p.Arg170Trp)

      ClinVar: 179285

      CAID: CA021778

      gnomAD: chr19-55154071-G-A

      AdditionalInfo: Monozygotic twin

    2. Patient 1

      Case1: Male, age 3 at diagnosis, ethnicity not stated

      DiseaseAssertion: Restrictive cardiomyopathy (RCM)

      FamilyInfo: Familial screening in the R170G proband documented a hypertrophic cardiomyopathy with restrictive filling pattern in patient’s father, but the family refused additional genetic testing. No other family history of cardiac disorders stated.

      ParentalTesting: The family refused additional genetic testing

      CasePresentingHPOs: HP:0001723, HP:0001650, HP:0001654

      CaseHPOFreeText: Patient 1 showed an impaired left ventricular function and pulmonary hypertension at three years of age. Heart biopsy showed mild cardiomyocyte hypertrophy and interstitial fibrosis. He was diagnosed with RCM and died one year later of ventricular fibrillation.

      CaseNotHPOs: NR

      CaseNotHPOFreeText: Target sequencing including a panel of 108 cardiomyopathy- and channelopathy-associated genes revealed no additional pathogenic or likely pathogenic variants

      CasePreviousTesting: Additional target sequencing including a panel of 108 cardiomyopathy- and channelopathy-associated genes was performed using Illumina MiSeq as previously described.

      Genotyping Method: Total genomic DNA was extracted from peripheral blood using FlexiGene DNA Kit (Qiagen) according to the manufacturer’s protocol. The TNNI3 gene was screened for mutations using dye terminator sequencing. In both cases additional target sequencing including a panel of 108 cardiomyopathy- and channelopathy-associated genes was performed using Illumina MiSeq as previously described

      FunctionalAnalysis: Functional analysis performed on recombinant proteins. Both cTnI-R170G/W strongly enhanced the Ca2+-sensitivity of skinned fibres, as is typical for RCM-mutations. Both mutants strongly enhanced the affinity of troponin (cTn) to tropomyosin compared to wildtype cTn. The stability of reconstituted thin filaments was reduced as revealed by electron microscopy.

      Variant: NM_000363.5:c.508C>G (p.Arg170Gly)

      ClinVar: 165517

      CAID: CA021769

      gnomAD: NR

      AdditionalInfo: NR

    1. We recruited a family of 11 individuals spanning five generations in which 8 family members have large ASDs (Figure 1A)

      Case#: Caucasian female (only information given)

      DiseaseAssertion: ASD

      FamilyInfo: Brother has DCM, and 2 affected family members suffered sudden death in mid-to-late adult life (Pedigree included)

      ParentalTesting: Maternal grandparents, mother, aunt, uncle, step-dad, and brother tested

      CasePresentingHPOs: not reported

      CaseHPOFreeText: not reported

      CaseNotHPOs: not reported

      CaseNotHPOFreeText: not reported

      CasePreviousTesting: Transesophageal echocardiography

      Genotyping Method: linkage analysis. Sanger sequencing, and whole genome sequencing

      FunctionalAnalysis: animal model (experiment with mouse, chick, and Xenopus embryos)

      Variant: c.13_15del; p.K5del ( c.20_22del; p.K7del)

      ClinVar: 181682 ?

      CAID: not found

      gnomAD: not found

      AdditionalInfo:

    1. The index case was an 88-year-old woman (II.5)

      Case1: Female, 85 at diagnosis, ethnicity not stated

      DiseaseAssertion: Hypertrophic cardiomyopathy (HCM)

      FamilyInfo: An index patient’s brother (II.6) was reported with moderate HCM and another brother (II.7) with sudden cardiac death at the age of 40 years. The clinical screening led to the diagnosis of HCM in two of the index patient’s descendants, a daughter and a son. Daughter (III.4, age 59) with septal hypertrophy of 16 mm confirmed by cardiac MRI, son (III.8, age 47) with septal hypertrophy of 15 mm. Daughter (III.6, age 50) is an unaffected carrier. Five other relatives (III.1, III.5, III.6, III.7, IV.1) were healthy with normal cardiac evaluation. Pedigree shown in Figure 1.

      ParentalTesting: Not preformed.

      CasePresentingHPOs: HP:0001639, HP:0001279

      CaseHPOFreeText: Admitted to the emergency unit with chest pain after a pre-syncopal episode at the age of 85. Electrocardiogram showed sinus rhythm, negative T waves in V1-V3 and signs of ventricular hypertrophy. Transthoracic echocardiography detected asymmetric septal hypertrophy of 25 mm with preserved ejection fraction, moderate diastolic dysfunction and mild left atrial enlargement. Twenty-four-hour Holter monitoring documented episodes of non-sustained ventricular tachycardia defined as ≥ 3 beats at a rate of ≥ 120 bpm

      CaseNotHPOs: NR

      CaseNotHPOFreeText: Coronary artery disease was ruled out

      CasePreviousTesting: NR

      Genotyping Method: The index patient’s genomic DNA was subjected to massively parallel sequencing to identify the genetic origin of the disease using a 251-gene cardiomyopathy diagnostic panel. Targeted massively parallel sequencing of the index patient’s genomic DNA was performed with an Agilent SureSelect custom library covering 251 genes. For the MYBPC3 gene: all exons including the complete sequence of introns. Sequencing performed on NovaSeq 6000 (Illumina), bioinformatics pipeline using BWA alignment and GATK variant calling, reference genome GRCh37/hg19. Sanger sequencing confirmed both variants

      FunctionalAnalysis: Minigene and patient blood RNA splicing assays performed. Both the minigene and patients’ RNA splicing assays revealed that the MYBPC3 c.3331−26T>G variant promoted complete intron 30 retention in the mRNA, and also partial retention of the second half of intron 30. Normal MYBPC3 mRNA was not detected in the MUT lanes. The corresponding normal MYBPC3 fusion protein was not detected with either of the two antibodies in cells transfected with the MUT plasmid.

      Variant: NM_000256.3:c.3331−26T>G

      ClinVar: 1320039

      CAID: CA2573146361

      gnomAD: chr11-47332999-A-C

      AdditionalInfo: This paper also identified two additional unrelated HCM probands carrying c.3331−26T>G in a large cohort of 9,611 HCM probands

  2. Nov 2026
    1. 7-year-old girl

      Case#: Jenni a 7 year-old female

      DiseaseAssertion: Dilated cardiomyopathy with LVNC

      FamilyInfo: MYH7 maternally inherited and MYBPC3 paternally inherited

      ParentalTesting: Mother has PPCM

      CasePresentingHPOs: HP:0004755, HP:0001716

      CaseHPOFreeText: heart failure and supraventicular tachycardia, (intermittent) Wolff-Parkinson- White syndrome

      CaseNotHPOs:not reported

      CaseNotHPOFreeText: not reported

      CasePreviousTesting: Echocardiogram and MRI

      Genotyping Method: Segregation analysis, targeted next generation sequencing

      FunctionalAnalysis: electrophysiology, transplant evaluation, CT angiography

      Variant: NM_000256.3(MYBPC3):c.2672G>A (p.Arg891Gln)

      ClinVar:177884

      CAID: CA012826

      gnomAD: 11-47357493-C-T

      AdditionalInfo:

    1. a male patient who was found to carry a novel pathogenic missense mutation in the MYBPC3 gene (chr11:4737288835, NM_000256.3: c.194 C > T, p.T65M)

      Case#: a male in the age range of 36-40

      DiseaseAssertion: Dilated cardiomyopathy and generated hiPSC-CMS

      FamilyInfo: not reported

      ParentalTesting: not reported

      CasePresentingHPOs: HP:0002875, HP:0031352

      CaseHPOFreeText: Exertional dyspnea, chest tightness, nocturnal dyspnea, and reduced exercise tolerance

      CaseNotHPOs: not reported

      CaseNotHPOFreeText: not reported

      CasePreviousTesting: echocardiogram and electrocardiograms

      Genotyping Method: peripheral blood was extracted and use to sequence the entire genome

      FunctionalAnalysis: hiPSCs were looked at in this case

      Variant: NM_000256.3: c.194 C > T (p.Thr65Met)

      ClinVar:407324

      CAID: CA047700

      gnomAD: 11-47372888-G-A

      AdditionalInfo:

    1. 65‐year‐old male

      Case1: Male, 65, Chinese DiseaseAssertion: Non‐obstructive HCM, heart failure, and atrial fibrillation FamilyInfo:Family history of HCM and sudden cardiac death CasePresentingHPOs: HP:0031295, HP:0001685, HP:0001712, HP:0012664, HP:0025169, HP:0005110, HP:0001658, HP:0001635 CaseHPOFreeText: Presented with stenosis in the circumflex artery and has a history of non‐obstructive HCM, heart failure NYHA class III, AF, myocardial infarction, and coronary atherosclerosis CasePreviousTesting: Exercise stress echocardiography test, transthoracic echocardiography, electrocardiogram, cardiovascular magnetic resonance (CMR), computerized tomography coronary angiogram, and peripheral blood draw Genotyping Method: Genomic DNA for whole-exome sequencing (WES) by NovaSeq 6000 platform from the peripheral blood draw of proband. FunctionalAnalysis:C to T transition at nucleotide 1522 in coding exon 16 of MYBPC3 replaces the glutamine residue with a premature translational stop signal (p.Gln508Ter) Variant: NM_000256.3:c.1522C>T MANE Select <br /> ClinVar:180941

    1. A 4-year-old boy

      Case#:4-year-old boy, half Japanese and half Chinese

      DiseaseAssertion:HCM

      FamilyInfo: “No family history of cardiac disease”

      ParentalTesting: “No family history of cardiac disease”

      CasePresentingHPOs: HP:0004308, HP:0001279, HP:0001688, HP:0004756, HP:0001663,

      “ventricular tachyarrhythmias, syncope, mild sinus bradycardia, sudden onset of ventricular tachycardia, ventricular fibrillation”

      CaseHPOFreeText:

      CaseNotHPOs:

      CaseNotHPOFreeText: Did not present with ischemia or electrolyte abnormalities.

      CasePreviousTesting: A peripheral blood test was performed

      Genotyping Method: Direct sequencing

      FunctionalAnalysis: “A novel heterozygous missense variant in ACTC1 (c.692C>G, p.T231R) was identified (Figure 2A), and it was considered to be possibly pathogenic on in silico analysis.”

      Variant:NM_005159.5(ACTC1):c.692C>G ClinVar:Not reported

      CAID:CA391630526

      gnomAD:not reported

      AdditionalInfo:

    1. The proband (II.2)

      Case1: Male, 24 years old at diagnosis, ethnicity not stated

      DiseaseAssertion: Dilated cardiomyopathy (DCM)

      FamilyInfo: Three affected family members carry the D94A mutation, mother (I.2, diagnosed age 21 with peripartum cardiomyopathy), sister (II.1, diagnosed age 29), and proband (II.2, diagnosed age 24). Sanger sequencing confirmed the MYL2 variant was present in all three affected family members (I.2, II.1, and II.2).

      ParentalTesting: Mother confirmed as heterozygous carrier of D94A mutation with DCM phenotype. Father not a carrier, unaffected

      CasePresentingHPOs: HP:0001644, HP:0006699

      CaseHPOFreeText: The proband (II.2) and his sister (II.1) were diagnosed at ages 24 and 29 after preventive cardiovascular screening revealed mild global left ventricular systolic dysfunction. Medical therapy was initiated upon evidence of decreased ejection fraction. Patients II.1 and II.2 (proband) displayed abnormal ECG findings and systolic dysfunction as manifested by reduced EF. However, the LV and septal wall thickness were within the normal range.

      CaseNotHPOs: NR

      CaseNotHPOFreeText: Septal wall thickness measurements were within normal range in all affected family members. LV wall thickness within normal range.

      CasePreviousTesting: No prior testing.

      Genotyping Method: Twenty two variants, meeting our established criteria for exome sequencing analysis, were identified in the three affected family members of the pedigree. Exome sequencing performed; variant confirmed by Sanger sequencing. Sanger sequencing confirmed the MYL2 variant was present in all three affected family members (I.2, II.1, and II.2)

      FunctionalAnalysis: Functional analysis performed on recombinant proteins, not directly on patient samples. Far-UV CD spectroscopy was used to analyze the effect of the D94A mutation on the secondary structure of the RLC. The mutation was observed to induce a reduction in the α-helical content of the RLC and imposed intra-molecular rearrangements. The mutation was seen to impair the binding of RLC to the MHC (myosin heavy chain), and its incorporation into the RLC-depleted porcine myosin. The actin-activated ATPase activity of mutant-reconstituted porcine cardiac myosin was significantly higher compared to ATPase of WT

      Variant: NP_000423.2:p.Asp94Ala

      ClinVar: 4710041

      CAID: CA386698152

      gnomAD: NR

      AdditionalInfo: Three affected family members carry the variant (mother I.2, sister II.1, proband II.2)

    1. 48-year-old man

      Case#:48-year-old male

      DiseaseAssertion: Reported cardiac hypertrophy, presented with atrial fibrillation and decompensated heart failure three years prior. Tested positive for cardiomyopathy with diffuse fibrosis with slow-flow.

      FamilyInfo: “Family history was positive for a mother with chronic atrial fibrillation from as early as her mid-thirties and a father who had arterial hypertension and died from an unrelated, non-cardiovascular disease.”

      ParentalTesting: “Genetic screening of first-degree relatives was recommended but was not done due to financial reasons. The mother of the patient did not fulfill phenotypical criteria for HCM, but had left and right atrial dilation, likely due to the decades-long atrial fibrillation with no other apparent reason for the dilation.”

      CasePresentingHPOs: HP:0001635 , HP:0002140, HP:0005110 decompensated heart failure, Ischemic stroke, persistent atrial fibrillation,

      CaseHPOFreeText:persistent atrial fibrillation, Hypertrophy of the heart, thrombosis of the left atrial appendage

      CaseNotHPOs:

      CaseNotHPOFreeText:

      CasePreviousTesting:Blood sample collected and DNA extracted using salting-out method. The following tests were performed on patient:

      Genotyping Method: “whole-exome sequencing anda targeted panel of 242 cardiomyopathy -associated genes”

      FunctionalAnalysis: “In silico analysis of the variant p.His103Gln in the ACTC1 gene by PolyPhen-2, SIFT, and MutationTaster predicted it as damaging, with position 103 being highly conserved and histidine and glutamine having a small physicochemical difference. MutationTaster predicted variant p.Leu39Ter in the PLN gene as damaging in line with the expected loss of protein function due to a premature termination codon at position 39. According to the ACMG/AMP criteria, variants p.His103Gln in the ACTC1 gene and p.Leu39Ter in the PLN gene may be classified as likely pathogenic and pathogenic, respectively.” “WES led to the detection of two heterozygous variants in the ACTC1 gene and in the PLN gene,”

      Variant:NM_005159.5(ACTC1):c.309C>A (p.His103Gln)

      ClinVar: 377435

      CAID:Not Reported

      gnomAD:Not Reported

      AdditionalInfo: Proband had two other variants associated with familial fibrillation and hypertrophic cardiomyopathy: c.116T > G, p.Leu39Ter in the PLN gene, and c.5827C > T, p.His1943Tyr in the SCN5A gene.

    1. 3.1. Patient A

      Case#: 7 month-old female, Italian

      DiseaseAssertion: dilated cardiomyopathy

      FamilyInfo: None listed

      ParentalTesting: “parents were heterozygous carriers of the variant”

      CasePresentingHPOs:

      “progressive dyspnea, sinus tachycardia, biventricular overload, left atrial dilatation, mild mitral regurgitation, dilated and markedly hypokinetic left ventricle, right ventricle was itself hypokinetic, lymphocytic myocarditis, endocardial fibroelastosis, acute-on-chronic heart failure, ischemic stroke, right-sided hemiparesis,

      CaseHPOFreeText: “dilated left ventricle with thin walls and impaired systolic function with LVEF equal to 25% according to Simpson’s disk summation method”

      CaseNotHPOs: “absence of edema or myocardial fibrosis”

      CaseNotHPOFreeText: “right chambers appeared normal”

      CasePreviousTesting: transthoracic echocardiography, electrocardiogram, MRI, myocardial biopsy, heart transplant

      Genotyping Method: Clinical exome sequencing analysis targeted at a selection of genes associated with cardiomyopathies

      FunctionalAnalysis: homozygous variant in the TNNI3 gene

      Variant: NM_000363.5:c.292C>T

      ClinVar: 181575

      CAID: Not reported

      gnomAD: 19-55154821-G-A

      AdditionalInfo:

    2. 3.2. Patient B

      Case#: 6 month-old male, Moroccan

      DiseaseAssertion: DCM

      FamilyInfo: Fourth child of first degree Moroccan parents, two sisters reported healthy, one died of heart failure at 8 months

      ParentalTesting:

      CasePresentingHPOs:HP:0002094 , HP:0011703 ,

      “Dyspnea, sinus tachycardia”

      CaseHPOFreeText: “overload of the left ventricle, dilatation of the left chambers with remarkable reduction of LVEF” after transplant: “Post-transplant pathological examination assessed dilatation of both ventricles, and microscopic evaluation found evidence of normally oriented cardiomyocytes with dysmetric proportions, extensive subendocardial cytoplasmic vacuolization from likely ischemic damage, interstitial edema, and mild fibrous thickening of the endocardium.”

      CaseNotHPOs:

      CaseNotHPOFreeText:

      CasePreviousTesting: “fetal and neonatal echocardiography, chest X-ray, TTE, heart transplant at 8 months, Post-transplant pathological examination,

      Genotyping Method: NGS

      FunctionalAnalysis: homozygous TNNI3 truncating variant in exon 5 of the TNNI3 gene, nonsense variant

      Variant: NM_000363.5:c.204del p.(Arg69Alafs*8)

      ClinVar: 179447

      CAID: Not reported

      gnomAD: not reported

      AdditionalInfo: The variant reported in proband was considered pathogenic.

    1. young girl

      Case#: Girl II.2 from family DCM84. Diagnosed in her third week of life. Ancestry NR.

      DiseaseAssertion: Dilated cardiomyopathy with left ventricular noncompaction.

      FamilyInfo: No known heart disease in her parents or older sister. None of them had the variant. See Figure 2.

      ParentalTesting: Both parents tested negative by Sanger sequencing. They declined parentage testing. The authors think the variant likely arose de novo.

      CasePresentingHPOs: HP:0001644, HP:0030682, HP:0025169, HP:0001635, HP:0001653, HP:0000980, HP:0001265, HP:0001252, HP:0000961, HP:0002094, HP:0001508

      CaseHPOFreeText: She was pale and had trouble breathing. She also had cyanosis and low muscle tone. Her reflexes were reduced. Her first echo showed that both ventricles were enlarged. Her left ventricular ejection fraction was 20%. A later echo showed mitral regurgitation. She had trouble gaining weight. She died from heart failure at 3 years and 8 months.

      CaseNotHPOs: NR

      CaseNotHPOFreeText: NR

      CasePreviousTesting: NR

      Genotyping Method: Whole exome sequencing found the variant. Sanger sequencing was used to test her family.

      FunctionalAnalysis: K30E made tropomyosin less stable. The thin filaments with K30E moved more slowly in the lab test. See Figures 3 through 5 and Tables 1 and 3.

      Variant: NM_001018005.2(TPM1):c.88A>G (p.Lys30Glu). Heterozygous.

      ClinVar: 3250489

      CAID: NR

      gnomAD: No record found in gnomAD v4.1.

      AdditionalInfo: PMID 39684770. The variant was first called a VUS. After the lab tests the authors proposed that it was pathogenic. Supplementary Table S1 shows how her echo results changed over time.

    1. The TPM1 D230N variant was present in all affected individuals in Families A

      Case1: Caucasian. Sex and exact age not specified for the proband

      DiseaseAssertion: Dilated cardiomyopathy (DCM)

      FamilyInfo: Family A was notable for severe HF and sudden death in young children. Individuals I-2, III-10 and IV-7 died suddenly at ages 3 years, 13 months, and 5 months respectively, without prior evidence of heart disease. Two siblings, IV-5 and IV-8, presented with DCM and advanced HF at 5 months of age (LVEF 27% and 29%). Individuals III-3 and IV-1 developed end-stage HF refractory to medical therapy as teenagers. III-3 presented at age 13 with refractory HF, underwent mitral and tricuspid valve replacement for functional regurgitation and died weeks later of multisystem organ failure. IV-1 was asymptomatic when diagnosed with DCM at 7 years during family screening, but developed severe HF at age 17 and underwent transplant at 18 years of age. Individuals III-4, III-7 and III-12 developed mild exercise intolerance in their 5th decade.

      ParentalTesting: NR

      CasePresentingHPOs: HP:0001635, HP:0001644

      CaseHPOFreeText: No family members with TPM1 D230N had evidence of cardiac conduction disease, and with one exception, none had evidence of skeletal myopathy

      CaseNotHPOs: NR

      CaseNotHPOFreeText: No family members with TPM1 D230N had evidence of cardiac conduction disease, and with one exception, none had evidence of skeletal myopathy.

      CasePreviousTesting: No prior testing.

      Genotyping Method: Genomic DNA was isolated from blood using standard methods in probands with DCM. Direct DNA sequence analysis of all coding regions and intron/exon boundaries was performed in 6 sarcomere genes.

      FunctionalAnalysis: Functional analysis performed on recombinant proteins but not patient tissue. In vitro studies demonstrated major inhibitory effects on sarcomere function with reduced Ca2+-sensitivity, maximum activation, and Ca2+ affinity compared to wildtype TPM1.

      Variant: NM_000366.5:c.688G>A (p.Asp230Asn)

      ClinVar: NR

      CAID: UnregisteredVariant

      gnomAD: NR

      AdditionalInfo: The paper does not explicitly identify which pedigree member is the Family A proband

    2. The TPM1 D230N variant was present in all affected individuals in Families A and B

      Case2: Caucasian. Sex and exact age not specified for the proband

      DiseaseAssertion: Dilated cardiomyopathy (DCM)

      FamilyInfo: Young members of this family also presented with severe HF. Individual III-1 developed failure to thrive at 10 weeks of age and echocardiography revealed severe LV dilation (LVIDD Z-score 15.6) and systolic dysfunction (LVEF 15%). Transplantation was considered, but she had substantial recovery with basic medical therapy. By age 8 years, she was asymptomatic with only mild LV systolic dysfunction (LVIDD Z-score 1.3, LVEF 46%). At age 20, II-6 underwent cardiac transplantation shortly after presenting with refractory HF symptoms and severe LV systolic dysfunction (LVEF < 20%). Individual II-7 died of HF at 12 years, prior to genetic testing. In addition to DCM, he had congenital cataracts and skeletal muscle weakness. I-1 had unexplained syncope at age 56 years. Cardiac studies revealed ventricular tachycardia and DCM (LVEF 25%) which improved with medical management. Three other adults (II-2, II-3, II-4, ages 38, 36 and 33 years, respectively) had asymptomatic LV systolic dysfunction.

      ParentalTesting: NR

      CasePresentingHPOs: HP:0001635, HP:0001644

      CaseHPOFreeText: NR

      CaseNotHPOs: NR

      CaseNotHPOFreeText: NR

      CasePreviousTesting: No prior testing.

      Genotyping Method: Genomic DNA was isolated from blood using standard methods in probands with DCM. Direct DNA sequence analysis of all coding regions and intron/exon boundaries was performed in 6 sarcomere genes.

      FunctionalAnalysis: Functional analysis performed on recombinant proteins but not patient tissue. In vitro studies demonstrated major inhibitory effects on sarcomere function with reduced Ca2+-sensitivity, maximum activation, and Ca2+ affinity compared to wildtype TPM1.

      Variant: NM_000366.5:c.688G>A (p.Asp230Asn)

      ClinVar: NR

      CAID: UnregisteredVariant

      gnomAD: NR

      AdditionalInfo: The paper does not explicitly identify which pedigree member is the Family B proband

    1. 1

      Case#: Patient 1; 89-year-old female; identical twin (Patient 2) with mild HCM

      DiseaseAssertion: Hypertrophic cardiomyopathy (HCM) associated with the pathogenic MYBPC3 nonsense variant NM_000256.3.787G>T (p.Gly263Ter). Patient 1 is an 89-year-old female with severe symptomatic obstructive HCM, previously requiring septal ablation. Her maximum reported left ventricular wall thickness was 29 mm by echocardiography in 2015.

      FamilyInfo: Patient 1 belongs to a family with hereditary hypertrophic cardiomyopathy associated with the MYBPC3 p.Gly263Ter founder variant. Her monozygotic twin sister (Patient 2) carries the same pathogenic variant but has a substantially milder HCM phenotype, with a maximum left ventricular wall thickness of 13 mm and no reported symptoms at an advanced age. The twin pair belongs to the extended family that also includes Patients 3 and 4, another pair of monozygotic twins carrying the same variant. The pedigree documents additional affected relatives and a history of sudden death, although not all family members have confirmed genetic testing.

      ParentalTesting: NR – The family pedigree supports familial occurrence of hypertrophic cardiomyopathy, but the specific parent from whom Patient 1 inherited the MYBPC3 p.Gly263Ter variant cannot be conclusively determined from the available genetic testing data. Her monozygotic twin sister (Patient 2) was confirmed to carry the same variant.

      CasePresentingHPOs: HP:0001639 (Hypertrophic cardiomyopathy); HP:0002094 (Dyspnea); HP:0001712 (Left ventricular hypertrophy); HP:0032092 (Left ventricular outflow tract obstruction)

      CaseHPOFreeText: Echocardiography documented a maximum left ventricular wall thickness of 29 mm in 2015. She previously experienced significant dyspnea, with symptoms classified as NYHA III/IV, associated with severe left ventricular outflow tract obstruction. She underwent septal ablation, which improved her clinical symptoms. At the time of the study, she remained minimally symptomatic.

      CaseNotHPOs: HP:0000822 (Hypertension)

      CaseNotHPOFreeText: Explicitly reported that Patient 1 did not have hypertension. No additional negative phenotypic findings were specifically documented for this patient.

      CasePreviousTesting: Previous cardiac evaluations included echocardiography demonstrating severe left ventricular hypertrophy, with a maximum wall thickness of 29 mm in 2015, and clinical identification of severe left ventricular outflow tract obstruction. The patient underwent septal ablation for symptomatic obstructive hypertrophic cardiomyopathy. Electrocardiographic findings were also evaluated following the procedure. The article does not provide a detailed history of genetic testing performed before the reported familial MYBPC3 investigation.

      Genotyping Method: Genetic testing of index cases was performed using targeted next-generation sequencing (NGS) with Ion Torrent technology. The earlier index cases were evaluated using a nine-gene sarcomeric panel, including MYBPC3. Familial screening for the MYBPC3 NM_000256.3.787G>T (p.Gly263Ter) variant was performed using Sanger sequencing on an ABI3130XL sequencer. Monozygosity of the twin pairs was independently confirmed using the PowerPlex 16 HS System, which analyzes 16 microsatellite markers. Article does not specify whether Patient 1's individual MYBPC3 genotype was initially established through NGS or other targeted Sanger sequencing.

      FunctionalAnalysis: The MYBPC3 NM_000256.3.787G>T (p.Gly263Ter) variant is a nonsense mutation that introduces a premature termination codon. The authors classified this founder variant as pathogenic based on its predicted loss-of-function effect, absence from the population reference databases examined, and segregation among affected family members. Computational evidence supported a deleterious effect. However, no patient-specific functional assays measuring MYBPC3 RNA expression, protein abundance, or protein function were reported in this study. The molecular consequences were inferred from the variant type and existing evidence rather than directly demonstrated experimentally in Patient 1.

      Variant: MYBPC3 NM_000256.3:c.787G>T p.Gly263Ter; Nonsense; Autosomal dominant; Clinical significance: Pathogenic (1 submission). Review status: 1 out of 4 stars (criteria provided, single submitter).

      ClinVar: 1460339

      CAID: CA380333920

      gnomAD: GRCh38 variant 11-47347891-C-A. African/African American population: AC = 0; AF = 0.0000.

      AdditionalInfo: Patient’s monozygotic twin sister (Patient 2) carries the same variant but exhibits a substantially milder clinical phenotype. Patient 1 had a maximum left ventricular wall thickness of 29 mm in 2015, severe left ventricular outflow tract obstruction, and symptomatic dyspnea requiring septal ablation. In contrast, Patient 2 had a maximum wall thickness of 13 mm and was asymptomatic. This illustrates variable expressivity of MYBPC3-associated hypertrophic cardiomyopathy, even among genetically identical individuals. The authors discuss environmental and epigenetic factors as possible contributors to phenotypic variability, although no specific modifying mechanism was experimentally demonstrated in these patients.

    2. 5

      Case#: Patient 5; 47-year-old male; identical twin (Patient 6) with less severe hypertrophy

      DiseaseAssertion: Hypertrophic cardiomyopathy (HCM)

      FamilyInfo: Patient has a monozygotic twin brother (Patient 6), who is also affected by HCM. Both individuals carry the same pathogenic MYBPC3 nonsense variant, NM_000256.3.787G>T (p.Gly263Ter). However, Patient 5 demonstrates more pronounced left ventricular hypertrophy than Patient 6. Cardiac magnetic resonance imaging (CMR) revealed maximum left ventricular wall thicknesses of 28 mm and 19 mm, respectively.

      ParentalTesting: NR – Parental genetic testing results were not explicitly reported for Patient 5 or his monozygotic twin brother (Patient 6)

      CasePresentingHPOs: HP:0001639 (Hypertrophic cardiomyopathy); HP:0001712 (Left ventricular hypertrophy)

      CaseHPOFreeText: Patient diagnosed with hypertrophic cardiomyopathy (HCM), characterized by substantial left ventricular hypertrophy. Echocardiography performed in 2022 demonstrated a maximum left ventricular wall thickness of 18 mm, while cardiac magnetic resonance imaging (CMR) showed a maximum thickness of 28 mm.

      CaseNotHPOs: HP:0032092 (Left ventricular outflow tract obstruction); HP:0000822 (Hypertension)

      CaseNotHPOFreeText: Patient 5 did not exhibit left ventricular outflow tract obstruction (LVOTO), even though having substantial left ventricular hypertrophy (max wall thickness of 28 mm). The study also explicitly reports that none of the six patients, including Patient 5, had hypertension.

      CasePreviousTesting: Patient 5 underwent clinical cardiac evaluation, including echocardiography, cardiac magnetic resonance imaging (CMR), and electrocardiography (ECG).

      Genotyping Method: Genetic analysis was performed using next-generation sequencing (NGS) with Ion Torrent technology for index patients and targeted Sanger sequencing for familial screening. The study reports that recent index cases associated with Patients 5–6 were evaluated using an expanded 195-gene NGS panel, as described in Supplementary Table S2. The pathogenic MYBPC3 variant NM_000256.3.787G>T (p.Gly263Ter) was identified in both monozygotic twins. However, the article does not explicitly specify whether Patient 5 underwent the full NGS panel or targeted familial testing. Monozygosity was independently confirmed using the PowerPlex 16 HS System.

      FunctionalAnalysis: NR – No patient-specific functional assays were reported for Patient 5 (computational evidence supporting a deleterious effect, absence from the ESP, 1000 Genomes, and ExAC population databases, and segregation of the variant among affected family members).

      Variant: MYBPC3 NM_000256.3:c.787G>T p.Gly263Ter; Premature termination codon; Nonsense; Autosomal dominant; Clinical significance: Pathogenic (1 submission). Review status: 1 out of 4 stars (criteria provided, single submitter).

      ClinVar: 1460339

      CAID: CA380333920

      gnomAD: gnomAD: GRCh38 variant 11-47347891-C-A. African/African American population: AC = 0; AF = 0.0000.

      AdditionalInfo: Patient’s monozygotic twin brother (Patient 6) carries the same pathogenic variant but exhibits less pronounced left ventricular hypertrophy. The authors suggest that additional environmental or epigenetic modifiers may influence disease severity, although no specific modifying mechanism was experimentally established.

    1. proband II: 3 was a 43-year-old man

      Case#: 43-year-old man family b

      DiseaseAssertion: Familial dilated cardiomyopathy (FDCM)

      FamilyInfo: Sister II:1 had previously been diagnosed with DCM and carried both reported variants. Brother II:2 died of sudden cardiac death.

      ParentalTesting: father was negative for either varient

      CasePresentingHPOs: HP:0031352, HP:0002094, HP:0002321 HP:0001644 “Dyspnea; chest tightness; dizziness; dilated cardiomyopathy

      CaseHPOFreeText: Severe DCM symptoms

      CaseNotHPOs: not reported

      CaseNotHPOFreeText: Father I:1 and daughter III:1 were reported to have no clinical symptoms

      CasePreviousTesting: Previously diagnosed with FDCM

      Genotyping Method: NGS. PCR, Sanger

      FunctionalAnalysis: Putative pathogenic mutations were analysed computationally using the PolyPhen-2, SIFT, and MutationTaster

      Variant: MYH7 NM_000257:c.3134G>A; p.Arg1045His; heterozygous missense

      ClinVar: 651054

      CAID: N/A

      gnomAD: 14-23422291-C-T

      AdditionalInfo: two variants may have a “dose effect” and associate their combination with the proband’s severe phenotype

    2. patient from Family A

      Case#:44-year-old woman , family 1 proband

      DiseaseAssertion: Familial hypertrophic cardiomyopathy

      FamilyInfo: Father, sister, and brother, died of sudden cardiac death around age 40

      ParentalTesting: not reported

      CasePresentingHPOs: HP:0031352, HP:0002094, HP:0005144 “Dyspnea; chest tightness, increased interventricular septum thickness”

      CaseHPOFreeText: Symptoms after exercise, interventricular septum thickness 14.8 mm; left atrium 32 mm.

      CaseNotHPOs: not reported

      CaseNotHPOFreeText:not reported

      CasePreviousTesting: no previous testing was reported

      Genotyping Method: NGS. PCR, Sanger

      FunctionalAnalysis: Putative pathogenic mutations were analysed computationally using the PolyPhen-2, SIFT, and MutationTaster

      Variant: TNNI3 NM_000363.4:c.433C>G; p.Arg145Gly heterozygous exon 7 missense

      ClinVar:12419

      CAID: N/A

      gnomAD: 19-55154146-G-C

      AdditionalInfo: reported variant and a potential HCM hotspot

    1. Patient 1

      Case1: 5 week old female

      DiseaseAssertion: Feeding problems and cyanosis. X-thorax showed a grossly enlarged heart

      FamilyInfo: Family history of both parents was positive for HCM and sudden death

      ParentalTesting: Initial echocardiography revealed no abnormalities in the 32-year-old mother, who was heterozygous for c.2373dup, nor in the 31-year-old father, heterozygous for c.2827C>T. ECG in the father showed mild repolarization abnormalities (ST elevation of 0.5 mm in V1, followed by a negative T in V1–V4). Re-evaluation after 7 years revealed moderate septal hypertrophy (HCM) with an interventricular septum of 14 mm in the mother, and interventricular septal measurements at the upper limit of the normal range (12 mm) in the father.

      CasePresentingHPOs: HP:0001640, HP:0001639,

      CaseHPOFreeText: Severe cardiomegaly and dilatation with a total weight of 115  g (normal weight at this age, 30  g). Right ventricular thickening was noted, especially of the posterior wall. The anterior wall of the left ventricle was severely thickened and showed abnormal trabeculation and multiple intertrabecular recesses as seen in noncompaction cardiomyopathy. Secundum ASD was confirmed. No other congenital malformations were found. Microscopic examination of cardiac tissue (Figure 1a) showed myofibrillar disarray in both the ventricular septum and the left ventricular wall. Hypertrophic myocytes with a diameter of 20–30 μm (normal 12  μm) and multiple vacuoles on electron microscopy suggested glycogenosis

      CaseNotHPOs: NR

      CaseNotHPOFreeText: NR

      CasePreviousTesting: NR

      Genotyping Method: NR

      FunctionalAnalysis: Microscopic postmortem examination of heart muscle from patient 1. Hypertrophic myocytes with myofibrillar disarray typical of HCM due to sarcomeric protein variations were present, albeit without a significant amount of interstitial fibrosis (hematoxylin and eosin staining, magnification × 100). (b) Electron micrograph showing a large, irregular vacuole.

      Variant: NC_000011.10:g.47337730dup, NM_000256.3(MYBPC3):c.2827C>T (p.Arg943Ter)

      ClinVar: 37039, 42619

      CAID: CA013001, CA012139

      gnomAD: 11-47356671-G-A, 11-47359280-A-AC

      AdditionalInfo: NR

    1. The patient clinically diagnosed as DCM. A heterozygous missense variant, c.3373G>A, in exon 30 of the MYBPC3 (NM‐000256), was determined in the patient.

      Case#: Female with DCM symptoms beginning at age 30

      DiseaseAssertion: Dilated cardiomyopathy (DCM) associated with a heterozygous missense variant in MYBPC3, c.3373G>A (p.Val1125Met). The authors propose autosomal dominant inheritance in this DCM case.

      FamilyInfo: NR – Detailed family relationships, segregation testing, and individual relatives' phenotypes are not described for the current DCM proband.

      ParentalTesting: NR

      CasePresentingHPOs: HP:0001644 (Dilated cardiomyopathy); HP:0002094 (Dyspnea); HP:0001962 (Palpitations); HP:0004756 (Ventricular tachycardia)

      CaseHPOFreeText: The patient experienced symptoms beginning at age 30, including frequent palpitations and dyspnea. ECG monitoring revealed multiple premature ventricular contractions and nonsustained ventricular tachycardia. Echocardiography demonstrated severe spherical left ventricular enlargement, severe systolic and diastolic dysfunction, LVEF of 10%, and mild pulmonary hypertension. She was classified as NYHA functional class II–III and received medical therapy and an implantable cardioverter-defibrillator.

      CaseNotHPOs: NR

      CaseNotHPOFreeText: NR

      CasePreviousTesting: NR – Article describes patient's clinical evaluation, including ECG monitoring and echocardiography, before genetic analysis.

      Genotyping Method: Genomic DNA was extracted from peripheral blood. Targeted next-generation sequencing was performed using a custom NimbleGen panel covering the coding regions and exon–intron boundaries of 23 genes associated with DCM. Sequencing was conducted on an Illumina HiSeq 2000 platform. Reads were aligned to the hg19 reference genome using BWA, and SAMtools was used for variant analysis. MYBPC3 variant confirmed using Sanger sequencing.

      FunctionalAnalysis: In silico analyses were performed to investigate the potential functional consequences of MYBPC3 p.Val1125Met. SIFT, PolyPhen-2, and MutationTaster predicted potentially damaging effects, while CADD produced a score of 33. Multiple-sequence alignment demonstrated that Val1125 is highly conserved across species. Protein modeling using I-TASSER and Phyre2 predicted structural differences involving the region surrounding residue 1125, located within the C9 fibronectin type III domain of cardiac myosin-binding protein C (cMyBP-C). The authors proposed that the substitution could affect protein structure and function. No direct experimental functional validation of this variant was reported.

      Variant: MYBPC3 NM_000256.3:c. 3373G>A (p.Val1125Met); rsID: rs121909378; missense; heterozygous

      ClinVar: 8604

      CAID: CA014038

      gnomAD: MYBPC3 c.3373G>A (p.Val1125Met), GRCh38: 11-47332931-C-T. In gnomAD v4, the reported allele frequencies are 0.00001920 (exomes), 0.00003943 (genomes), and 0.00002111 (total). The highest ancestry-specific allele frequency identified was in the Ashkenazi Jewish population (AC = 5; AF = 0.0001695).

      AdditionalInfo: Authors propose variant dosage, interactions with other variants, and genetic modifiers may contribute to differences in disease phenotype. However, the proposed autosomal dominant association with DCM was not supported by documented segregation testing in the current proband's family, and the functional analyses were computational rather than experimental.

    1. I-1

      Case#: 80-year-old male (I-1) diagnosed with HCM at approximately 50–55 years of age; familial case with his 3 adult offspring (II-2, II-3, and II-4)

      DiseaseAssertion: Hypertrophic cardiomyopathy (HCM) associated with a heterozygous frameshift variant in MYBPC3.

      FamilyInfo: The proband (I-1) is an elderly male with familial hypertrophic cardiomyopathy. Three adult offspring (II-2, II-3, and II-4) were evaluated and diagnosed with HCM based on interventricular septal hypertrophy. All four individuals carried the heterozygous MYBPC3 c.1042_1043insCGGCA variant. Individual II-2 experienced chest discomfort and palpitations, whereas II-3 and II-4 were asymptomatic at evaluation. These findings demonstrate segregation of the variant with HCM in the examined family members and are consistent with autosomal dominant inheritance.

      ParentalTesting: NR – Genetic testing of the proband's parents was not reported but the variant was identified in his three adult offspring, supporting familial segregation.

      CasePresentingHPOs: HP:0001639 (Hypertrophic cardiomyopathy); HP:0002094 (Dyspnea); HP:0001635 (Congestive heart failure)

      CaseHPOFreeText: The proband experienced chest tightness, dyspnea, and recurrent heart failure. Echocardiography demonstrated marked interventricular septal hypertrophy (39 mm during diastole and 41 mm during systole), a left atrial diameter of 44 mm, and a left ventricular ejection fraction of 60%. Additional findings included premature atrial beats, intraventricular conduction block, and NYHA functional class II. A history of hypertension was reported.

      CaseNotHPOs: HP:0001279 (Syncope); HP:0001681 (Angina pectoris); HP:0001695 (Cardiac arrest)

      CaseNotHPOFreeText: The proband had no reported history of syncope, angina pectoris, or cardiac arrest. No surgical myectomy was reported.

      CasePreviousTesting: NR – Previous genetic testing was not reported but the proband underwent clinical cardiovascular evaluation, including electrocardiography, echocardiography, and BNP measurement.

      Genotyping Method: Whole-genome sequencing (WGS) was performed using peripheral blood DNA on an Illumina NovaSeq 6000 platform with 150-bp paired-end reads and approximately 30× sequencing depth. Reads were aligned to the hs37d5 reference genome using BWA, and variants were annotated using ANNOVAR.

      FunctionalAnalysis: Cardiac tissue from the proband was analyzed using RT-qPCR and Western blotting. MYBPC3 mRNA expression and cardiac myosin-binding protein C (cMyBP-C) abundance were significantly reduced (P < 0.05), supporting a haploinsufficiency mechanism. These findings do not independently establish the functional effect of the specific variant, and the Western blot analysis lacked biological replicates.

      Variant: MYBPC3 NM_000256.3.1038_1042dup (p.Met348ThrfsTer4). Five-base-pair duplication resulting in a frameshift and premature termination codon. Reported in Zhang et al. (2025) as c.1042_1043insCGGCA.

      ClinVar: No exact match identified for MYBPC3 c.1042_1043insCGGCA using the reported HGVS notation. ClinVar Variation ID not established.

      CAID: CA273429

      gnomAD: No exact matching entry identified in gnomAD v4 for MYBPC3 NM_000256.3:c.1038_1042dup (CA273429). Population allele frequency could not be established.

      AdditionalInfo: The variant was identified in the proband and three adult offspring with interventricular septal thickening. The study proposed MYBPC3 haploinsufficiency as a disease mechanism based on reduced transcript and protein abundance. The available familial and functional evidence supports an association with HCM, although the specific variant's pathogenicity requires interpretation alongside the limitations of the study.

    1. Patient 3

      Case#: Patient 3; male; 60 years old at first observation; 14 mm LV wall thickness; family history of HCM

      DiseaseAssertion: Hypertrophic cardiomyopathy (HCM) associated with the heterozygous MYBPC3 intronic splice-altering variant c.1224-80G>A, classified as likely pathogenic by the study authors.

      FamilyInfo: Patient was reported to have positive family history of HCM. Echocardiography demonstrated a maximum left ventricular wall thickness of 14 mm without left ventricular outflow tract obstruction. The study did not identify specific affected relatives or provide a family pedigree.

      ParentalTesting: NR – Patient had a positive family history of HCM but parental genotypes and variant segregation were not documented.

      CasePresentingHPOs: HP:0001639 (Hypertrophic cardiomyopathy); HP:0001712 (Left ventricular hypertrophy)

      CaseHPOFreeText: Echocardiography demonstrated a maximum left ventricular wall thickness of 14 mm without left ventricular outflow tract (LVOT) obstruction. NYHA functional classification was not reported.

      CaseNotHPOs: HP:0032092 (Left ventricular outflow tract obstruction)

      CaseNotHPOFreeText: Echocardiographic evaluation showed no left ventricular outflow tract (LVOT) obstruction.

      CasePreviousTesting: Patient 3 previously underwent targeted next-generation sequencing using the Illumina TruSight Cardio panel, which included 174 genes associated with inherited cardiac conditions. The initial genetic analysis was negative. Subsequent reanalysis of existing sequencing data identified the MYBPC3 intronic variant c.1224-80G>A.

      Genotyping Method: Genomic DNA obtained from peripheral blood was analyzed using the Illumina TruSight Cardio targeted next-generation sequencing panel on an Illumina MiniSeq platform. Previously generated sequencing data were reexamined using an intronic hotspot analysis approach, with variant visualization in Integrative Genomics Viewer (IGV). The MYBPC3 c.1224-80G>A variant was subsequently confirmed by Sanger sequencing.

      FunctionalAnalysis: The MYBPC3 intronic variant c.1224-80G>A creates a cryptic splice acceptor site within intron 13, resulting in retention of 78 intronic nucleotides upstream of exon 14. This produces an in-frame insertion of 26 codons. Previous functional studies demonstrated altered RNA splicing and an approximately 50% reduction in MYBPC3 transcript abundance. SpliceAI predicted a strong splice-altering effect (Δscore = 0.94). The current study did not perform patient-specific RNA functional experiments. Instead, researchers identified the variant through reanalysis of existing next-generation sequencing data and confirmed its presence using Sanger sequencing.

      Variant: MYBPC3 NM_000256.3.1224-80G>A.

      ClinVar: 693982

      CAID: CA221697326

      gnomAD: The MYBPC3 variant c.1224-80G>A (GRCh38: 11-47343342-C-T) is present at a low frequency in gnomAD v4; Exome allele frequency: 0.00001637; Genome allele frequency: 0.00005261; Total allele frequency: 0.00002005; The highest ancestry-specific allele frequency reported was in the African/African American population, with an allele count (AC) of 8 and allele frequency (AF) of 0.0001113.

      AdditionalInfo: Although Patient 3 carried the same variant as Patient 2, their reported cardiac phenotypes differed. Patient 2 exhibited a maximum left ventricular wall thickness of 27 mm and LVOT obstruction with a gradient of 50 mmHg. These differences are consistent with variable clinical expression of MYBPC3-associated HCM, although the study did not determine their underlying causes.

    2. Patient 1

      Case#: Patient 1; female; 56 years old at first observation with diagnosis of HCM; 13 mm LV wall thickness

      DiseaseAssertion: Hypertrophic cardiomyopathy (HCM) associated with the heterozygous MYBPC3 intronic splice-altering variant c.1224-80G>A, classified as likely pathogenic by the study authors.

      FamilyInfo: The study reports a negative family history of HCM. No family pedigree or detailed clinical information about relatives was provided.

      ParentalTesting: NR

      CasePresentingHPOs: HP:0001639 (Hypertrophic cardiomyopathy); HP:0001712 (Left ventricular hypertrophy); HP:0031656 (Systolic anterior motion of the mitral valve)

      CaseHPOFreeText: Hypertrophic cardiomyopathy and a maximum left ventricular wall thickness of 13 mm. Echocardiography demonstrated systolic anterior motion (SAM) of the mitral valve without left ventricular outflow tract (LVOT) obstruction. The patient had no reported family history of hypertrophic cardiomyopathy. NYHA functional classification was NR.

      CaseNotHPOs: HP:0032092 (Left ventricular outflow tract obstruction)

      CaseNotHPOFreeText: No left ventricular outflow tract (LVOT) obstruction was reported despite the presence of systolic anterior motion of the mitral valve.

      CasePreviousTesting: Patient 1 previously underwent targeted next-generation sequencing using the Illumina TruSight Cardio panel covering 174 genes associated with inherited cardiac conditions. Initial genetic analysis was negative. Subsequent reanalysis of existing sequencing data identified the MYBPC3 intronic variant c.1224-80G>A.

      Genotyping Method: Genomic DNA from peripheral blood was analyzed using the Illumina TruSight Cardio targeted next-generation sequencing panel on an Illumina MiniSeq platform. Existing sequencing data were reexamined using an intronic hotspot analysis approach and Integrative Genomics Viewer (IGV). The MYBPC3 c.1224-80G>A variant was subsequently confirmed by Sanger sequencing.

      FunctionalAnalysis: The MYBPC3 intronic variant c.1224-80G>A creates a cryptic splice acceptor site within intron 13, resulting in the retention of 78 intronic nucleotides upstream of exon 14. This produces an in-frame insertion of 26 codons in the resulting transcript. Previous functional studies demonstrated abnormal RNA splicing and approximately 50% reduction in MYBPC3 transcript abundance. SpliceAI predicted a strong splice-altering effect (Δscore = 0.94). The current study did not perform patient-specific RNA functional experiments. Instead, the researchers identified the variant through reanalysis of existing next-generation sequencing data and confirmed its presence using Sanger sequencing.

      Variant: MYBPC3 NM_000256.3.1224-80G>A.

      ClinVar: 693982

      CAID: CA221697326

      gnomAD: The MYBPC3 variant c.1224-80G>A (GRCh38: 11-47343342-C-T) is present at a low frequency in gnomAD v4; Exome allele frequency: 0.00001637; Genome allele frequency: 0.00005261; Total allele frequency: 0.00002005; The highest ancestry-specific allele frequency reported was in the African/African American population, with an allele count (AC) of 8 and allele frequency (AF) of 0.0001113.

      AdditionalInfo: Unlike Patients 2 and 3, Patient 1 had no reported family history of HCM. Echocardiography demonstrated systolic anterior motion of the mitral valve without left ventricular outflow tract obstruction, and maximum left ventricular wall thickness was 13 mm. Although all three patients carried the same splice-altering variant, their reported cardiac phenotypes differed. This observation is consistent with variable clinical expression of MYBPC3-associated HCM, although the study did not establish the underlying causes of these differences.

    3. Patient 2

      Case#: Patient 2; male; 74 years old at first observation; 27 mm LV wall thickness; family history of HCM

      DiseaseAssertion: Hypertrophic cardiomyopathy (HCM) associated with the MYBPC3 intronic splice-altering variant c.1224-80G>A (authors classify as likely pathogenic).

      FamilyInfo: Reported family history of hypertrophic cardiomyopathy. Echocardiographic evaluation demonstrated a maximum left ventricular wall thickness of 27 mm and left ventricular outflow tract (LVOT) obstruction, with a gradient of 50 mmHg. The patient was classified as NYHA functional class II.

      ParentalTesting: NR – Patient had a positive family history of HCM but parental genotypes and variant segregation were not documented.

      CasePresentingHPOs: HP:0001639 (Hypertrophic cardiomyopathy); HP:0032092 (Left ventricular outflow tract obstruction); HP:0001712 (Left ventricular hypertrophy)

      CaseHPOFreeText: Echocardiography demonstrated a maximum left ventricular wall thickness of 27 mm and left ventricular outflow tract (LVOT) obstruction with a measured gradient of 50 mmHg. The patient was classified as New York Heart Association (NYHA) functional class II, indicating mild limitation of physical activity.

      CaseNotHPOs: NR

      CaseNotHPOFreeText: NR

      CasePreviousTesting: The patient previously underwent targeted next-generation sequencing using the Illumina TruSight Cardio panel covering 174 genes associated with hereditary cardiac diseases. The initial analysis produced a negative molecular result. Subsequent reanalysis of the existing sequencing data identified the MYBPC3 intronic variant c.1224-80G>A.

      Genotyping Method: Genomic DNA was extracted from peripheral blood and sequenced using the Illumina TruSight Cardio panel on a MiniSeq platform. Initial bioinformatics analysis was performed using Illumina BaseSpace software. Raw sequencing data were subsequently reanalyzed using an intronic-variant hotspot approach, with variant visualization in Integrative Genomics Viewer (IGV). The identified MYBPC3 variant was validated by Sanger sequencing.

      FunctionalAnalysis: The MYBPC3 intronic variant c.1224-80G>A creates a novel splice acceptor site within intron 13, resulting in the retention of 78 intronic nucleotides upstream of exon 14. This produces an in-frame insertion of 26 codons and is associated with approximately 50% reduction in MYBPC3 transcript abundance. Previous studies demonstrated the splice-altering effect through functional analyses, while SpliceAI predicted a strong effect on splicing (Δscore = 0.94). The current study identified the variant through reanalysis of existing NGS data and confirmed its presence using Sanger sequencing; it did not perform new patient-specific RNA functional experiments.

      Variant: MYBPC3 NM_000256.3.1224-80G>A.

      ClinVar: 693982

      CAID: CA221697326

      gnomAD: The MYBPC3 variant c.1224-80G>A (GRCh38: 11-47343342-C-T) is present at a low frequency in gnomAD v4; Exome allele frequency: 0.00001637; Genome allele frequency: 0.00005261; Total allele frequency: 0.00002005; The highest ancestry-specific allele frequency reported was in the African/African American population, with an allele count (AC) of 8 and allele frequency (AF) of 0.0001113.

      AdditionalInfo: The variant was detected by expanding the analysis to include previously characterized intronic splice-altering regions and was subsequently confirmed by Sanger sequencing. Functional evidence for altered splicing was obtained from previously published research rather than new patient-specific RNA experiments.

    1. Case IV.2 is an 8-year-old male from family B (Fig. 1b), who was diagnosed with DCM at the age of 6. He underwent heart transplantation soon after diagnosis. The only other clinical feature noted was horseshoe kidney. The affected brother (IV.1) died at the age of 2 of SCD and renal failure.

      Case#: Family B, Case IV.2; 8-year-old male; diagnosed at age 6

      DiseaseAssertion: Dilated cardiomyopathy (DCM)

      FamilyInfo: Positive family history of sudden cardiac death (SCD). The proband's brother (IV.1) died at age 2 of SCD and renal failure. Both parents (III.1 and III.2) were asymptomatic heterozygous carriers of MYL3 c.106G>T. Two unaffected siblings were tested: IV.3 was wild-type and IV.4 was heterozygous (Fig. 1b; Supplementary Fig. S2b).

      ParentalTesting: Both parents (III.1 and III.2) were confirmed heterozygous carriers of MYL3 c.106G>T by PCR and bidirectional Sanger sequencing, supporting autosomal recessive inheritance (Supplementary Genetic Findings; Fig. S2b).

      CasePresentingHPOs: HP:0001644 (Dilated cardiomyopathy); HP:0000085 (Horseshoe kidney); HP:0005162 (Reduced left ventricular ejection fraction).

      CaseHPOFreeText: DCM diagnosed at age 6; heart transplantation performed shortly after diagnosis. Clinical evaluation revealed horseshoe kidney, severe left ventricular dysfunction (LVEF 15–20%), moderate right ventricular dysfunction (TAPSE 9 mm), chamber cardiomegaly on coronary CT angiography, and rapid ventricular tachycardia on ECG (Main text, Family B; Supplementary Results, p. 6).

      CaseNotHPOs: NR

      CaseNotHPOFreeText: NR

      CasePreviousTesting: NR (no prior diagnostic genetic testing reported before the study's exome sequencing)

      Genotyping Method: Exome sequencing identified the homozygous MYL3 c.106G>T (p.Glu36Ter) variant in the proband (IV.2). PCR and bidirectional Sanger sequencing validated the variant and confirmed segregation in the parents and two unaffected siblings (Supplementary Methods; Supplementary Genetic Findings; Fig. S2b).

      FunctionalAnalysis: Zebrafish cmlc1 knockdown and rescue experiments were performed using human MYL3 RNA containing c.106G>T (p.Glu36Ter). Unlike wild-type MYL3 RNA, the mutant RNA failed to rescue the cardiac phenotype, with persistent cardiac edema, ventricular dysfunction, and atrial dilation (Fig. 2; Supplementary Methods; Supplementary Movie S7).

      Variant: MYL3 NM_000258.2:c.106G>T (p. Glu36Ter); homozygous nonsense variant

      ClinVar: NR

      CAID: CA352499542

      gnomAD: NR

      AdditionalInfo: The authors classified the homozygous MYL3 c.106G>T (p.Glu36Ter) nonsense variant as pathogenic. The variant introduces a premature termination codon at amino acid 36. The proband was born to asymptomatic, consanguineous (first-cousin) parents of Bakhtiyari ancestry. Family segregation and zebrafish functional studies provide supporting evidence (Supplementary Results; Supplementary Genetic Findings; Supplementary Table S2).

    2. Case VI.1, from family C, was a female of apparently healthy second cousin parents. She was diagnosed with unclassified cardiomyopathy at the age of 2.5 years and died at the age of 8 years of SCD. Family history was positive for cardiac disease and occurrence of SCD in three family members (V.5, V.6, and V.8), who had been diagnosed with unclassified cardiomyopathy between the ages of 2 and 3 and had died between 5 and 9 years of age (Fig. 1c). There was no record of cardiac evaluation available for these individuals. The 40-year-old mother (V.2) was offered genetic testing following the death of her daughter (VI.1). Unfortunately, there was no tissue available from the deceased individual VI.1.

      Case#: Family C, Case VI.1; female; diagnosed at age 2.5 years; died at age 8

      DiseaseAssertion: Unclassified cardiomyopathy

      FamilyInfo: Family C has a positive family history of childhood-onset cardiomyopathy and sudden cardiac death. The affected individual (VI.1) was diagnosed with cardiomyopathy at age 2.5 years and died at age 8. Three maternal relatives (V.5, V.6, and V.8) are depicted as affected and deceased in the pedigree (Fig. 1C). Both parents (V.1 and V.2) were clinically unaffected heterozygous carriers of the MYL3 c.482-1G>A splice-acceptor variant. The genotype of VI.1 could not be confirmed because DNA was unavailable.

      ParentalTesting: PCR and bidirectional Sanger sequencing confirmed that both parents (V.1 and V.2) were heterozygous carriers of MYL3 c.482-1G>A. Direct testing of the affected daughter (VI.1) was not possible because DNA was unavailable. Her homozygous genotype was therefore suspected but not confirmed (Fig. 1C; Supplementary Genetic Findings).

      CasePresentingHPOs: HP:0001638 (Cardiomyopathy); HP:0001645 (Sudden cardiac death).

      CaseHPOFreeText: Female diagnosed with unclassified cardiomyopathy at age 2.5 years; died of sudden cardiac death at age 8 (Family C, Fig. 1C).

      CaseNotHPOs: NR (no patient-specific negative HPO findings confirmed for VI.1).

      CaseNotHPOFreeText: The authors reported no evidence of muscle weakness by neurological examination or history among affected individuals from the three families; however, it is unclear whether this assessment specifically included VI.1.

      CasePreviousTesting: NR (no prior genetic testing reported for VI.1).

      Genotyping Method: Genetic analysis of the affected individual's mother (V.2) identified MYL3 c.482-1G>A. PCR and bidirectional Sanger sequencing validated the variant and confirmed both parents (V.1 and V.2) as heterozygous carriers. VI.1 was not directly genotyped because DNA was unavailable (Supplementary Genetic Findings; Fig. 1C and S2C).

      FunctionalAnalysis: A minigene splicing assay in human HEK293FT cells demonstrated that MYL3 c.482-1G>A causes abnormal RNA splicing. The predominant outcome (~75%) was skipping of the 78-bp exon 5, producing an in-frame deletion (p.Gly161_Glu186del). A less frequent outcome (~25%) was deletion of the first nucleotide of exon 5, causing a frameshift (p.Gly161Valfs*4). Both outcomes are predicted to disrupt EF-hand domains. The authors note that the minigene assay may not fully reflect in vivo splicing frequencies (Supplementary Results, pp. 7–8; Fig. 2E–I).

      Variant: MYL3 c.482-1G>A (rs727503300)

      ClinVar: 164486

      CAID: CA013932

      gnomAD: NR MYL3 c.482-1G>A was not found in the gnomAD v4 (GRCh38) region results at chr3:46,860,813. Allele frequency not reported for this variant in the searched dataset.

      AdditionalInfo: The affected individual (VI.1) died at age 8, and DNA was unavailable for direct genetic testing. Both clinically unaffected parents (V.1 and V.2) were confirmed heterozygous carriers of MYL3 c.482-1G>A, suggesting that VI.1 may have inherited the variant from both parents; however, her genotype remains unconfirmed. A minigene assay demonstrated that the variant disrupts RNA splicing, predominantly causing exon 5 skipping, with a less frequent frameshift-producing splicing event. These functional findings support a damaging effect of the variant but do not establish VI.1's genotype (Fig. 1C; Fig. 2E–I; Supplementary Genetic Findings and Minigene Assay Results).

    3. Case III.7, a 38-year-old female from family A, was diagnosed with HCM at the age of 26 following dyspnea. Family history was positive for HCM and occurrence of SCD in four family members (Fig. 1a).

      Case#: Family A, Case III.7; 38-year-old female; diagnosed at age 26

      DiseaseAssertion: Hypertrophic cardiomyopathy (HCM)

      FamilyInfo: Positive family history of HCM and SCD. Mother (II.4), brother (III.8), uncle (II.7), and cousin (III.11) died of SCD at ages 55, 26, 57, and 24, respectively. The proband's three children (IV.3, IV.4, IV.5) were homozygous for the MYL3 variant but had normal echocardiograms at ages 18, 13, and 6.

      ParentalTesting: Supplementary Table S2 reports parental testing supportive of PM3 (variants in trans). However, DNA was unavailable for the proband's deceased mother (II.4), and individual parental genotypes were not specified in the supplementary genetic findings.

      CasePresentingHPOs: HP:0001639 (Hypertrophic cardiomyopathy); HP:0002094 (Dyspnea); HP:0001653 (Mitral regurgitation); HP:0001712 (Left ventricular hypertrophy)

      CaseHPOFreeText: HCM diagnosed at age 26 following dyspnea. At age 38, echocardiography showed reverse-curvature HCM with asymmetric left ventricular hypertrophy involving anterior, anterolateral, and lateral segments; maximum wall thickness 22 mm; severe mitral regurgitation; LVEF 55%; E/e' ratio 16.4; resting LVOT gradient 9 and post-maneuver gradient 30. Holter monitoring showed no arrhythmias (Supplementary Results, pp. 5–6; Table S1; Fig. S1).

      CaseNotHPOs: HP:0001324 (Muscle weakness)

      CaseNotHPOFreeText: Neurological evaluation revealed normal muscle tone, strength 5/5 in upper and lower limbs, no distal or proximal muscle atrophy or fasciculations, and normal creatine phosphokinase levels.

      CasePreviousTesting: Exome sequencing was performed; no rare, likely pathogenic variants in other cardiomyopathy-associated genes identified after filtering.

      Genotyping Method: Exome sequencing identified the MYL3 variant; bidirectional Sanger sequencing validated the variant. Familial genotyping supported recessive inheritance (Fig. 1a).

      FunctionalAnalysis: Zebrafish cmlc1 knockdown and rescue experiments were performed using human MYL3 RNA carrying c.170C>A (p.Ala57Asp). Mutant RNA showed partial phenotypic rescue but no statistically significant improvement in ventricular contractility compared with knockdown alone (Fig. 2a-d).

      Variant: MYL3 NM_000258.2:c.170C>A (p.Ala57Asp); homozygous missense variant; rs139794067

      ClinVar: 43121

      CAID: CA013575

      gnomAD: Allele frequency 0.000163 (0 homozygotes), as reported in Supplementary Table S2.

      AdditionalInfo: Family A, Case III.7. Clinical characteristics and genetic findings described in the Results section (Fig. 1a and 1d-e). Functional experiments described in Fig. 2. The authors classified c.170C>A as a variant of uncertain significance (VUS).

    1. The proband

      Case#: Female, 20, non-Hispanic white

      DiseaseAssertion: Peripartum cardiomyopathy

      FamilyInfo: NR

      ParentalTesting: NR

      CasePresentingHPOs: HP:0034807, HP:0001640

      CaseHPOFreeText: NA

      CaseNotHPOs: NA

      CaseNotHPOFreeText: NA

      CasePreviousTesting: NR

      Genotyping Method: Sanger sequencing

      FunctionalAnalysis: demonstrated decreased calcium sensitivity, which indicated that this mutation was likely to be disease causing

      Variant: NM_001276345.2:c.505C>G

      ClinVar: 2953222

      CAID: CA344204620

      gnomAD: NR

      AdditionalInfo: PPCM was diagnosed one week postpartum.

    1. 2-year-old female with severe RCM that is genetically caused by a homozygous TNNI3 nonsense variant, c.406C>T (p.Arg136∗)

      Case1: 2-year-old female

      DiseaseAssertion: restrictive cardiomyopathy, dilated cardiomyopathy

      FamilyInfo:The maternal family history was negative for any form of cardiomyopathy or sudden death. Paternal family history was unknown, the mother (1-II:2) and maternal half-brother (1-III:2) were both heterozygous for the TNNI3 p.Arg136∗ variant, mother (1-II:2, age 20) and half-brother (1-III:2, age 21 months) demonstrated normal heart function on echocardiography. ParentalTesting: Clinical exome sequencing done on mother of proband

      CasePresentingHPOs: HP:0032025, HP:0002140, HP:0005180, HP:0001653, HP:0005117

      CaseHPOFreeText: left-sided facial and extremity weakness, enlarged cardiac silhouette with interstitial opacities, dilated left and right atria, unusual morphology of the chordae tendineae of both atrioventricular valves was noted, leading to a tethering phenomenon

      CaseNotHPOs: HP:0001712,

      CaseNotHPOFreeText: normal systolic function

      CasePreviousTesting: Chest Xray, Echocardiogram, Head CT

      Genotyping Method: clinical exome sequencing

      FunctionalAnalysis: Immunostaining on heart tissue from patient, Quantitative analysis of heart tissue, Transmission electron microscopy with immersion fixed heart samples

      Variant:homozygous TNNI3 nonsense variant, c.406C>T (p.Arg136∗)

      ClinVar:488853

      CAID:CA407440677

      gnomAD:chr19-55154173-G-A v4

    1. proband with infantile hypertrophic cardiomyopathy

      Case1: Male, Infant, Tunisian

      DiseaseAssertion: infantile-onset HCM and mitral valve dysplasia

      FamilyInfo: Family with consanguinity in which four children had died before one year of age. The father (37 years old) and mother (27 years old) of the proband are consanguineously related. Two infants (VI:1 and VI:2) died at less than 30 days of age from cardiorespiratory arrest, and two (VI:3 and VI:4, proband) of them displayed abnormal cardiac findings on chest roentgenogram. While all four children displayed hepatomegaly and general hypotonia, VI:3 and VI:4 had a marked increase in heart size and died from refractory cardiogenic shock. The status of the MYL2 allele in siblings is unknown. The proband (fs/fs) was homozygous for the MYL2-fs allele while the parents were found to be heterozygous (fs/wt) carriers. The father (37 years old) and mother (27 years old) of the proband are consanguineously related, were asymptomatic from a cardiac standpoint and had normal cardiac anatomy and function as evaluated by an echocardiogram

      ParentalTesting: Homozygous variant in the proband and that the parents are heterozygous carriers using Sanger DNA sequencing of the genomic region. Father (37 years old) and mother (27 years old) were asymptomatic from a cardiac standpoint and had normal cardiac anatomy and function as evaluated by an echocardiogram

      CasePresentingHPOs: HP:0200128, HP:0001653, HP:0002092, HP:0001639, HP:0002240

      CaseHPOFreeText: Showed a rapid decline in health and was treated for various periods in neonatal intensive care units. The patient also displayed severe mitral valve regurgitation with abnormal thickening of the mitral valve leaflets and pulmonary arterial hypertension. Post-mortem examination of the proband’s heart confirmed severe biatrial dilatation, significant biventricular hypertrophy with small ventricular cavities and severe mitral valve dysplasia

      CaseNotHPOs: NR

      CaseNotHPOFreeText: no gross developmental defects

      CasePreviousTesting: No prior genetic testing reported before exome sequencing

      Genotyping Method: Performed exome sequencing on the proband. Exome libraries were constructed using the Agilent SureSelectQXT Target Enrichment System for Illumina Multiplexed Sequencing Protocol (Agilent Technologies, CA). DNA libraries were captured with the Agilent Clinical Research Exome Kit. Paired-end 150 base pair reads were generated for exome-enriched libraries sequenced on the Illumina HiSeq 4000 to a targeted depth of 100× coverage

      FunctionalAnalysis: Functional analysis performed. Immunohistochemical analysis of MYL2 expression in the proband’s ventricular myocardium shows a remarkable reduction in the expression of MYL2 as compared to control. Also, MYL2 mRNA was detected in the ventricle of the proband by RT-PCR. This suggests that the frameshift variant adversely affects the levels of MYL2 protein in the proband. Using immunoblot analysis, we observed that overexpression of the MYL2-fs variant was significantly reduced compared to stop-gain variants and the missense variant. When the H9c2 cells were treated with MG-132 after transfection with the MYL2-fs construct, the GFP signal corresponding to MYL2-fs was recovered. The in vitro experiments indicate that the MYL2-fs variant is not stable and that proteasome-mediated degradation of the translated product plays a key role in the instability of the protein. The overexpression of the fs variant identified in our proband or the MYL2-G162R missense variant failed to rescue the phenotype. Results reported in Figures 2, 3, and 4.

      Variant: NM_000432.3:c.431_432delCT

      ClinVar: NR

      CAID: UnregisteredVariant

      gnomAD: NR

      AdditionalInfo: 4 siblings who died before 1 year of age but MYL2 genotyping was only confirmed in the proband (VI:4)

  3. Oct 2026
    1. Classification of noncanonical splice site variants according to the splice defects The percentage of correctly spliced ABCA4 RNA product for NCSS variants was calculated by using a capillary electrophoresis system (Fig. 4; Supplemental Table S3; Supplemental Fig. S5). Three variants, c.4634G>A, c.5196+3_5196+8del, and c.5585−10T>C, showed 100% correctly spliced ABCA4 mRNAs. We could rule out pathogenicity for the last two variants but not for c.4634G>A p.(Ser1545Asn), as this variant is significantly enriched in >3000 Caucasian STGD1 patients compared to the non-Finnish ExAC population (Cornelis et al. 2017). Sixteen variants showed between 4.3% and 79.6% normal RNA and were tentatively classified as severe, moderately severe, and mild, while the remaining 26 NCSS variants did not show any normal RNA and were thus deemed severe variants. For c.2382+5G>C and c.2588G>C, no quantification was performed as the wild-type BA12 clone also showed exon skipping. Based on the Sanger sequence validation, we were able to annotate all the variants at the RNA level and predict their effect at the protein level (Table 1). Figure 4. Open in a new tab Percentages of remaining normal ABCA4 transcripts due to noncanonical splice site variants based on capillary electrophoresis system analyses. The percentages of normal ABCA4 transcript for 45 noncanonical splice site variants are represented by black bars. Nineteen variants showed varying fractions (4.3%–100%) of correct ABCA4 mRNA. Four of them also result in missense changes as depicted, but only p.(Ser1545Asn) and p.(Lys2160Glu) are likely to have an effect on protein function, as significant amounts of ABCA4 protein will be produced. For the remaining 26 variants (in the square box), no residual RNA was observed. (#) For this variant, densitometric scanning was performed.Table 1. In vitro tested noncanonical splice site variants and their observed RNA and predicted protein effects Open in a new tabWe correlated the predicted effect of the NCSS variants with the phenotypes in reported cases and, when the variants were not present in a homozygous state, with the severity of the second allele. For 25 of 47 variants, sufficient clinical data were available, and in all these cases, our predicted effect of the NCSS variants correlated with the observed phenotypes (Supplemental Table S4).

      RT-PCR of midigenes demonstrated that this variant impacts splicing by causing a deletion (r.5461_5714del) which is predicted to result in a frameshift (p.Thr1821Aspfs*6). This variant showed 0% correctly spliced ABCA4 mRNA. This frameshift variant introduces a premature stop codon between codons 1-2255 (PVS1(RNA); 29162642). There do appear to be alternative splice products (supplemental figure s2), where exon 39 or 40, or both 39 and 40, are skipped, but in all cases, this leads to a frameshift.